Epirubicin
- Generic Name
- Epirubicin
- Brand Names
- Ellence, Pharmorubicin PFS
- Drug Type
- Small Molecule
- Chemical Formula
- C27H29NO11
- CAS Number
- 56420-45-2
- Unique Ingredient Identifier
- 3Z8479ZZ5X
- Background
An anthracycline which is the 4'-epi-isomer of doxorubicin. The compound exerts its antitumor effects by interference with the synthesis and function of DNA.
- Indication
For use as a component of adjuvant therapy in patients with evidence of axillary node tumor involvement following resection of primary breast cancer.
- Associated Conditions
- Breast Cancer, Breast Cancer, Stage II, Breast Cancer, Stage III, Colorectal Cancer, Hormone-Refractory Prostate Cancer, Neoplasm of Stomach, Non-Small Cell Lung Carcinoma, Ovarian Cancer, Papillary transitional cell carcinoma of bladder, Recurrent Superficial Bladder Cancer, Small Cell Lung Cancer (SCLC), Soft Tissue Sarcoma, Carcinoma in situ of urinary bladder
- Associated Therapies
- -
A Feasibility Study to Evaluate Adjuvant Chemoradiotherapy for Gastric Cancer
- Conditions
- Interventions
- First Posted Date
- 2005-07-22
- Last Posted Date
- 2013-06-18
- Lead Sponsor
- Trans Tasman Radiation Oncology Group
- Target Recruit Count
- 52
- Registration Number
- NCT00123318
- Locations
- 🇦🇺
Liverpool Hospital, Liverpool, New South Wales, Australia
🇦🇺Royal North Shore Hospital, Sydney, New South Wales, Australia
🇦🇺Royal Brisbane Hospital, Herston, Queensland, Australia
Comparison of Two Combination Chemotherapy Regimens in Treating Women With Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2004-07-12
- Last Posted Date
- 2022-08-11
- Lead Sponsor
- NSABP Foundation Inc
- Target Recruit Count
- 2722
- Registration Number
- NCT00087178
- Locations
- 🇺🇸
Northside Hospital Cancer Center, Atlanta, Georgia, United States
🇺🇸CCOP - Atlanta Regional, Atlanta, Georgia, United States
🇺🇸Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Medical Center, Columbus, Ohio, United States
Combination Chemotherapy With or Without Trastuzumab in Treating Women With Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2003-02-06
- Last Posted Date
- 2013-07-19
- Lead Sponsor
- UNICANCER
- Target Recruit Count
- 3010
- Registration Number
- NCT00054587
- Locations
- 🇫🇷
Centre Hospitalier de Mulhouse, Mulhouse, France
🇫🇷Institut Prive de Cancerologie, Grenoble, France
🇫🇷Centre Paul Papin, Angers, France
Evaluation of the Addition of Herceptin to Standard Chemotherapy in the Neoadjuvant Setting for Operable Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2002-05-31
- Last Posted Date
- 2012-07-20
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 74
- Registration Number
- NCT00038402
- Locations
- 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.